The risk score for in-hospital mortality in patients with ST-segment elevation myocardial infarction

Aim    To develop a scale (score system) for predicting the individual risk of in-hospital death in patients with ST segment elevation acute myocardial infarction (STEMI) with an account of results of percutaneous coronary intervention (PCI).
Material and methods    The analysis used data of 1 649 sequential patients with STEMI included into the hospital registry of PCI from 2006 through 2017. To test the model predictability, the original sample was divided into two groups: a training group consisting of 1150 (70 %) patients and a test group consisting of 499 (30 %) patients. The training sample was used for computing an individual score. To this purpose, β-coefficients of each variable obtained at the last stage of the multivariate logistic regression model were subjected to linear transformation. The scale was verified using the test sample.
Results    Seven independent predictors of in-hospital death were determined: age ≥65 years, acute heart failure (Killip class III-IV), total myocardial ischemia time ≥180 min, anterior localization of myocardial infarction, failure of PCI, SYNTAX scale score ≥16, glycemia on admission ≥7.78 mmol/l for patients without a history of diabetes mellitus and ≥14.35 mmol/l for patients with a history of diabetes mellitus. The contribution of each value to the risk of in-hospital death was ranked from 0 to 7. A threshold total score of 10 was determined; a score ≥10 corresponded to a high probability of in-hospital death (18.2 %). In the training sample, the sensitivity was 81 %, the specificity was 80.6 %, and the area under the curve (AUC) was 0.902. In the test sample, the sensitivity was 96.2 %, the specificity was 83.3 %, and the AUC was 0.924.
Conclusion    The developed scale has a good predictive accuracy in identifying patients with acute STEMI who have a high risk of fatal outcome at the hospital stage.

1. Drapkina O.M., Samorodskaya I.V., Starinskaya М.А., Boytsov S.A. Comparison of Russian regions by standardized mortality rates from all causes and circulatory system diseases in 2006-2016. Preventive Medicine. 2018;21(4):4–12. DOI: 10.17116/profmed20182144

2. Kontsevaya A.V., Drapkina O.M., Balanova Yu.A., Imaeva A.E., Suvorova E.I., Khudyakov M.B. Economic Burden of Cardiovascular Diseases in the Russian Federation in 2016. Rational Pharmacotherapy in Cardiology. 2018;14(2):156–66. DOI: 10.20996/1819-6446-201814-2-156-166

3. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(2):119–77. DOI: 10.1093/eurheartj/ehx393

4. Averkov O.V., Duplyakov D.V., Gilyarov M.Yu., Novikova N.A., Shakhnovich R.M., Yakovlev A.N. et al. 2020 Clinical practice guidelines

5. for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(11):251–310. DOI: 10.15829/29/1560-4071-2020-4103

6. Szummer K, Wallentin L, Lindhagen L, Alfredsson J, Erlinge D, Held C et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014. European Heart Journal. 2017;38(41):3056–65. DOI: 10.1093/eurheartj/ehx515

7. Addala S, Grines CL, Dixon SR, Stone GW, Boura JA, Ochoa AB et al. Predicting mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI risk score). The American Journal of Cardiology. 2004;93(5):629–32. DOI: 10.1016/j.amjcard.2003.11.036

8. Palmerini T, Genereux P, Caixeta A, Cristea E, Lansky A, Mehran R et al. A New Score for Risk Stratification of Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions. 2012;5(11):1108–16. DOI: 10.1016/j.jcin.2012.07.011

9. Ran P, Yang JQ, Li J, Li G, Wang Y, Qiu J et al. A risk score to predict in-hospital mortality in patients with acute coronary syndrome at early medical contact: results from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome (CCC-ACS) Project. Annals of Translational Medicine. 2021;9(2):167. DOI: 10.21037/atm-21-31

10. Hizoh I, Banhegyi G, Domokos D, Major L, Andrassy P, Andreka P et al. TCT-804 Comparative Validation of the ALPHA Score, a Novel Risk Model Including Vascular Access Site for Predicting 30-Day Mortality in Patients Treated with Primary PCI. Journal of the American College of Cardiology. 2018;72(13): B320–1. DOI: 10.1016/j.jacc.2018.08.2039

11. Al’Aref SJ, Singh G, van Rosendael AR, Kolli KK, Ma X, Maliakal G et al. Determinants of In‐Hospital Mortality Aſter Percutaneous Coronary Intervention: A Machine Learning Approach. Journal of the American Heart Association. 2019;8(5):e011160. DOI: 10.1161/JAHA.118.011160

12. Fox KAA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F et al. Prediction of risk of death and myocardial infarction in the six months aſter presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091. DOI: 10.1136/bmj.38985.646481.55

13. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102(17):2031–7. DOI: 10.1161/01.CIR.102.17.2031

14. Halkin A, Singh M, Nikolsky E, Grines CL, Tcheng JE, Garcia E et al. Prediction of Mortality Aſter Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: The CADILLAC risk score. Journal of the American College of Cardiology. 2005;45(9):1397– 405. DOI: 10.1016/j.jacc.2005.01.041

15. Kirtane AJ, Sandhu P, Mehran R, McEntegart M, Cristea E, Bre

16. ner SJ et al. Association Between Intraprocedural Thrombotic Events and Adverse Outcomes Aſter Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction (a Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Substudy). The American Journal of Cardiology. 2014;113(1):36–43. DOI: 10.1016/j.amjcard.2013.08.034

17. Sabell T, Banaszewski M, Lassus J, Nieminen MS, Tolppanen H, Jäntti T et al. Prognostic impact of angiographic findings, procedural success, and timing of percutaneous coronary intervention in cardiogenic shock. ESC Heart Failure. 2020;7(2):768–73. DOI: 10.1002/ehf2.12637

18. Bessonov I.S., Sapozhnikov S.S., Kuznetsov V.A., Zyryanov I.P., Dyakova A.O., Musikhina N.A. et al. Register of percutaneous coronary interventions in patients with acute ST-segment elevation myocardial infarction. Certificate of registration of the database 2020621653, 11.09.2020. Application No. 2020621535 dated 02.09.2020.

19. Bessonov I.S., Kuznetsov V.A., Gorbatenko E.A., Sapozhnikov S.S., Zyryanov I.P. Percutaneous coronary interventions for ST elevation myocardial infarction in different age groups. Siberian Scientific Medical Journal. 2021;41(2):56–65. DOI: 10.18699/SSMJ20210208

20. Haller PM, Jäger B, Farhan S, Christ G, Schreiber W, Weidinger F et al. Impact of age on short- and long-term mortality of patients with ST-elevation myocardial infarction in the VIENNA STEMI network. Wiener klinische Wochenschriſt. 2018;130(5–6):172–81. DOI: 10.1007/s00508-017-1250-7

21. Fach A, Bünger S, Zabrocki R, Schmucker J, Conradi P, Garstka D et al. Comparison of Outcomes of Patients With ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention Analyzed by Age Groups (85 Years); (Results from the Bremen STEMI Registry). The American Journal of Cardiology. 2015;116(12):1802–9. DOI: 10.1016/j.amjcard.2015.09.022

22. Nielsen CG, Laut KG, Jensen LO, Ravkilde J, Terkelsen CJ, Kristensen SD. Patient delay in patients with ST-elevation myocardial infarction: Time patterns and predictors for a prolonged delay. European Heart Journal: Acute Cardiovascular Care. 2017;6(7):583–91. DOI: 10.1177/2048872616676570

23. Kheiri B, Osman M, Abdalla A, Haykal T, Chahine A, Gwinn M et al. Drug-Eluting Versus Bare-Metal Stents in Older Patients: A Me-ta-Analysis of Randomized Controlled Trials. Cardiovascular Revascularization Medicine. 2019;20(9):744–51. DOI: 10.1016/j.car-rev.2018.11.005

24. Entezarjou A, Mohammad MA, Andell P, Koul S. Culprit vessel: impact on short-term and long-term prognosis in patients with ST-elevation myocardial infarction. Open Heart. 2018;5(2):e000852. DOI: 10.1136/openhrt-2018-000852

25. Ram P, Shah M, Sirinvaravong N, Lo KB, Patil S, Patel B et al. Leſt ventricular thrombosis in acute anterior myocardial infarction: Evaluation of hospital mortality, thromboembolism, and bleeding. Clinical Cardiology. 2018;41(10):1289–96. DOI: 10.1002/clc.23039

26. Jenča D, Melenovský V, Stehlik J, Staněk V, Kettner J, Kautzner J et al. Heart failure aſter myocardial infarction: incidence and predictors. ESC Heart Failure. 2021;8(1):222–37. DOI: 10.1002/ehf2.13144

27. Nemik D.B., Matyushin G.V., Ustyugov S.A. Role of SYNTAX score scale in the stratification of the nosocomial risk of cardiovascular complications and lethality in patients with ST-segment elevation myocardial infarction. Rational Pharmacotherapy in Cardiology. 2018;14(3):324–9. DOI: 10.20996/1819-6446-2018-14-3-324-329

28. Tarasov R.S., Ganyukov V.I., Vakkosov K.M., Barbarash O.L., Barbarash L.S. SYNTAX residual in long-term outcomes prognosis of endovascular revascularization in myocardial infarction with ST elevation and multivessel disease. Cardiovascular Therapy and Prevention. 2016;15(5):33–8. DOI: 10.15829/1728-8800-2016-5-33-38

29. Jeger RV, Radovanovic D, Hunziker PR, Pfisterer ME, Stauffer J-C, Erne P et al. Ten-Year Trends in the Incidence and Treatment of Cardiogenic Shock. Annals of Internal Medicine. 2008;149(9):618–26. DOI: 10.7326/0003-4819-149-9-200811040-00005

30. Kawecki D, Morawiec B, Gąsior M, Wilczek K, Nowalany-Kozielska E, Gierlotka M. Annual Trends in Total Ischemic Time and One-Year Fatalities: The Paradox of STEMI Network Performance Assessment. Journal of Clinical Medicine. 2019;8(1):78. DOI: 10.3390/jcm8010078

31. Bessonov I.S., Kuznetsov V.A., Gorbatenko E.A., Dyakova A.O., Sapozhnikov S.S. Influence of Total Ischemic Time on Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction. Kardiologiia. 2021;61(2):40–6. DOI: 10.18087/cardio.2021.2.n1314

32. Khalid U, Jneid H, Denktas AE. The relationship between total ischemic time and mortality in patients with STEMI: every second counts. Cardiovascular Diagnosis and Therapy. 2017;7(S2):S119–24. DOI: 10.21037/cdt.2017.05.10

33. Denktas AE, Anderson HV, McCarthy J, Smalling RW. Total Ischemic Time: the correct focus of attention for optimal ST-segment elevation myocardial infarction care. JACC: Cardiovascular Interventions. 2011;4(6):599–604. DOI: 10.1016/j.jcin.2011.02.012

34. Kim HK, Jeong MH, Ahn Y, Chae SC, Kim YJ, Hur SH et al. Relationship between time to treatment and mortality among patients undergoing primary percutaneous coronary intervention according to Korea Acute Myocardial Infarction Registry. Journal of Cardiology. 2017;69(1):377–82. DOI: 10.1016/j.jjcc.2016.09.002

35. Shiomi H, Nakagawa Y, Morimoto T, Furukawa Y, Nakano A, Shirai S et al. AS-015: Total Ischemic Time and Primary PCI: Optimal Time Period from Symptom-onset to Reperfusion Therapy. The American Journal of Cardiology. 2012;109(7): S7. DOI: 10.1016/j.amjcard.2012.01.012

36. Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Maz

37. zone T et al. Hyperglycemia and Acute Coronary Syndrome: A Scientific Statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2008;117(12):1610–9. DOI: 10.1161/CIRCULATIONAHA.107.188629

38. Koracevic GP. Proposal of a New Approach to Study and Categorize Stress Hyperglycemia in Acute Myocardial Infarction. The Journal of Emergency Medicine. 2016;51(1):31–6. DOI: 10.1016/j.jemermed.2015.03.047

39. Fajar JK, Heriansyah T, Rohman MS. The predictors of no reflow phenomenon aſter percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis. Indian Heart Journal. 2018;70(Suppl 3):S406–18. DOI: 10.1016/j.ihj.2018.01.032

40. Kloner RA, King KS, Harrington MG. No-reflow phenomenon in the heart and brain. American Journal of Physiology-Heart and Circulatory Physiology. 2018;315(3):H550–62. DOI: 10.1152/ajpheart.00183.2018

41. O’Neill WW, Schreiber T, Wohns DHW, Rihal C, Naidu SS, Civitello AB et al. The Current Use of Impella® 2.5 in Acute Myocardial Infarction Complicated by Cardiogenic Shock: Results from the USpella Registry. Journal of Interventional Cardiology. 2014;27(1):1–11. DOI: 10.1111/joic.12080

42. Barbarash O.L., Kashtalap V.V., Kochergina A.M., Leonova V.O., Erlikh A.D. Management of patients with ST-segment elevation acute coronary syndrome in interventional cardiology units: RECORD-3 registry data. Fundamental and Clinical Medicine. 2016;1(3):6–13.

43. Sagaydak O.V., Oschepkova E.V., Chazova I.E. Cardiogenic shock in patients with acute coronary syndrome (data from Russian Federal Acute Coronary Syndrome Registry). Therapeutic Archive. 2019;91(9):47–52. DOI: 10.26442/00403660.2019.09.000317

44. Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. New England Journal of Medicine. 2017;377(25):2419–32. DOI: 10.1056/NEJMoa1710261